X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Indoco Remedies with Religare Enterprises - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs RELIGARE ENT. - Comparison Results

INDOCO REMEDIES    Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

RELIGARE ENT. 
   Change

Promoted by Mr. Malvinder Mohan Singh and Mr. Shivinder Mohan Singh , Religare Enterprises is a financial services company, offering a wide range of financial products and services targeted at retail investors, high net worth individuals and corporat... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES RELIGARE ENT. INDOCO REMEDIES/
RELIGARE ENT.
 
P/E (TTM) x 23.3 21.9 106.3% View Chart
P/BV x 2.8 0.3 885.6% View Chart
Dividend Yield % 0.8 0.0 -  

Financials

 INDOCO REMEDIES   RELIGARE ENT.
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-17
RELIGARE ENT.
Mar-16
INDOCO REMEDIES/
RELIGARE ENT.
5-Yr Chart
Click to enlarge
High Rs360395 91.2%   
Low Rs249256 97.3%   
Sales per share (Unadj.) Rs119.0218.0 54.6%  
Earnings per share (Unadj.) Rs8.4-2.3 -356.8%  
Cash flow per share (Unadj.) Rs15.2-0.6 -2,624.9%  
Dividends per share (Unadj.) Rs1.600-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs70.7190.0 37.2%  
Shares outstanding (eoy) m92.15203.33 45.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.61.5 171.5%   
Avg P/E ratio x36.4-138.9 -26.2%  
P/CF ratio (eoy) x20.0-561.0 -3.6%  
Price / Book Value ratio x4.31.7 251.6%  
Dividend payout %19.10-   
Avg Mkt Cap Rs m28,08366,184 42.4%   
No. of employees `0006.0NA-   
Total wages/salary Rs m2,1679,336 23.2%   
Avg. sales/employee Rs Th1,817.0NM-  
Avg. wages/employee Rs Th359.0NM-  
Avg. net profit/employee Rs Th127.7NM-  
INCOME DATA
Net Sales Rs m10,96844,318 24.7%  
Other income Rs m40709 5.6%   
Total revenues Rs m11,00745,026 24.4%   
Gross profit Rs m1,56523,723 6.6%  
Depreciation Rs m633359 176.5%   
Interest Rs m6218,721 0.3%   
Profit before tax Rs m9095,351 17.0%   
Minority Interest Rs m0-1,085 0.0%   
Prior Period Items Rs m06 0.0%   
Extraordinary Inc (Exp) Rs m0-2,533 0.0%   
Tax Rs m1392,215 6.3%   
Profit after tax Rs m771-477 -161.7%  
Gross profit margin %14.353.5 26.7%  
Effective tax rate %15.341.4 36.8%   
Net profit margin %7.0-1.1 -653.4%  
BALANCE SHEET DATA
Current assets Rs m5,72594,957 6.0%   
Current liabilities Rs m5,454103,036 5.3%   
Net working cap to sales %2.5-18.2 -13.5%  
Current ratio x1.00.9 113.9%  
Inventory Days Days625 1,308.1%  
Debtors Days Days7238 187.9%  
Net fixed assets Rs m5,30717,890 29.7%   
Share capital Rs m1842,033 9.1%   
"Free" reserves Rs m6,33133,999 18.6%   
Net worth Rs m6,51638,629 16.9%   
Long term debt Rs m1,323118,583 1.1%   
Total assets Rs m11,970274,293 4.4%  
Interest coverage x15.61.3 1,216.7%   
Debt to equity ratio x0.23.1 6.6%  
Sales to assets ratio x0.90.2 567.1%   
Return on assets %7.06.7 104.6%  
Return on equity %11.8-1.2 -958.8%  
Return on capital %12.413.0 95.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m4,5070-   
Fx outflow Rs m1,14112 9,672.9%   
Net fx Rs m3,366-12 -28,521.2%   
CASH FLOW
From Operations Rs m886-21,540 -4.1%  
From Investments Rs m-1,7065,149 -33.1%  
From Financial Activity Rs m1,31618,531 7.1%  
Net Cashflow Rs m4972,139 23.2%  

Share Holding

Indian Promoters % 59.2 50.9 116.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 12.5 0.9 1,388.9%  
FIIs % 6.0 15.3 39.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 32.9 68.1%  
Shareholders   12,805 26,518 48.3%  
Pledged promoter(s) holding % 0.0 68.3 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   CREST VENTURES  NESCO LIMITED  THOMAS COOK INDIA  KOTHARI PRODUCTS  MOTILAL OSWAL  



Today's Market

Sensex Finishes on a Flat Note; Coal India Stock Rallies 4.2%(Closing)

Indian share markets finished some selling pressure in the final hour of trade to finish flat amid weak European markets.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Aug 17, 2017 (Close)

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES 5-YR ANALYSIS

COMPARE INDOCO REMEDIES WITH

MARKET STATS